نتایج جستجو برای: pegasys

تعداد نتایج: 54  

Journal: :Journal of Viral Hepatitis 2007
Th Witthöft B Möller K H Wiedmann St Mauss R Link J Lohmeyer M Lafrenz C M Gelbmann D Hüppe C Niederau U Alshuth

The combination treatment of peginterferon alpha-2a (PEG-IFN alpha-2a; Pegasys) plus ribavirin (RBV) is recommended as a standard care for HCV infections. Side effects and aspects of efficacy and safety have to be balanced. This study evaluates clinical practice data on safety and efficacy of HCV treatment with PEG-IFN in combination with RBV over 24 and 48 weeks. This study was a phase III, mu...

2017
Yan-Hua Ding Bin Liu Xin Zhang Li Sun Hong Zhang Hua Luo Yan-Fu Sun Cheng-Jiao Liu Qi Zhang Yu-Chen Cao Hong Chen Jun-Qi Niu

This study aimed to explore and evaluate the tolerability and antiviral activity of pegylated recombinant human consensus interferon-α (PEG-CIFN) in adults with hepatitis C virus (HCV) infection. A total of 48 adult subjects chronically infected with HCV were divided into five groups, which were treated separately with PEG-CIFN 1.0 µg/kg (n=10), 1.5 µg/kg (n=10), 2.0 µg/kg (n=9) or 3.0 µg/kg (n...

Journal: :Antimicrobial agents and chemotherapy 2005
M Rodriguez-Torres F J Torriani V Soriano M J Borucki E Lissen M Sulkowski D Dieterich K Wang J-M Gries P G Hoggard D Back

The intracellular triphosphorylation and plasma pharmacokinetics of lamivudine (3TC), stavudine (d4T), and zidovudine (ZDV) were assessed in a pharmacokinetic substudy, in 56 human immunodeficiency virus-hepatitis C virus (HIV-HCV) coinfected patients receiving peginterferon alfa-2a (40KD) 180 microg/week plus either placebo or ribavirin (RBV) 800 mg/day in the AIDS PEGASYS Ribavirin Internatio...

2013

Psoriasis is a T-cell-mediated autoimmune disease involving the skin. Two cytokines, interleukin-12 (IL-12) and IL-23 have been shown to play a pivotal role in the pathogenesis of the disease. Ustekinumab (Stelara) is a therapeutic monoclonal antibody (mAb) targeted against the p40 shared subunit of IL-12 and IL-23. Recently the ability of therapeutic proteins (TP) including mAbs that target ei...

2010
Ashwani Kumar Singal

H C virus (HCV) infects 170 million people worldwide (1). The infection becomes chronic in 85%–90% of cases with potential to cause cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC) (2). Treatment of HCV infection has evolved significantly over the last 20 years since the introduction of interferon-α in 1991. Initial studies using interferon were disappointing with response...

Journal: :gastroenterology and hepatology from bed to bench 0
mohsen vahedi asma pourhoseingholi sara ashtari mohamad amin pourhoseingholi phd. maryam karkhane bijan moghimi-dehkordi

aim : this study compared pr and nb in predicting hcv patient costs. the objective of this study was to predict the direct cost of the hcv patient in iran. background : hepatitis c virus (hcv) is a common and expensive infectious disease in iran. cost associated with hcv and its complications has not been well characterized. analysis of cost data is important in providing consistent information...

2010
Frank Tacke

C infections with the hepatitis C virus (HCV) represent a major global health problem, with around 170 million patients at risk of developing life-threatening complications such as liver cirrhosis or hepatocellular carcinoma. The standard treatment of care is a combination of weekly pegylated interferon (peginterferon) alfa and daily ribavirin for 24-72 weeks, dependent on HCV genotype and the ...

Journal: :The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2006
E Parise H Cheinquer D Crespo A Meirelles A Martinelli H Sette J Gallizi R Silva C Lacet E Correa H Cotrim J Fonseca R Paraná V Spinelli W Amorim F Tatsch M Pessoa

Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interf...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید